# US 2002/0164331 A1 · Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0164331 A1
- Document ID: US20020164331A1
- Status: Published application
- Kind: A1
- Application number: 09/885,768
- Filed: 2001-06-19
- Published: 2002-11-07
- Earliest claimed: 2000-06-19
- Inventors: Mark A. Exley; Samuel B. Wilson; Steven P. Balk
- Web page: https://patentgrep.com/patent/US20020164331A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/421: {Immunoglobulin superfamily}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/58: Prostate
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/599: with CD designations not provided for elsewhere
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.

## Claims

### Claim 1

A purified antibody that preferentially binds a T cell antigen receptor (TCR), wherein said antibody preferentially binds a CDR3-loop or an α-β junction of said TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 2 (depends on 1)

The purified antibody of claim 1, that preferentially binds and preferentially expands an invariant T cell.

### Claim 3 (depends on 1)

The purified antibody of claim 1, that preferentially binds the antigen binding site of the TCR of said T cell subpopulation.

### Claim 4

A combination of purified antibodies that preferentially binds a TCR, wherein said antibody combination preferentially binds a CDR3-loop or an α-β junction of said TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; wherein said antibody combination is selected from the group consisting of:
(i) an anti-Vα24 antibody and an anti-CD161 antibody;
(ii) an anti-Vα24 antibody and an anti-CD94 antibody;
(iii) an anti-Vβ11 antibody and an anti-CD161 antibody; and
(iv) an anti-Vβ11 antibody and an anti-CD94 antibody.

### Claim 5

A fragment or derivative of an antibody, wherein said antibody preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 6

A bifunctional antibody comprising:
(a) a first antibody or fragment thereof that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; wherein said first antibody or fragment binds a first epitope; and
(b) a second antibody or fragment thereof that binds a second epitope expressed on a T cell expressing said TCR or expressed on a NK T cell, CD1d-reactive T cell, or JαQ+ T cell that is bound by said first antibody or fragment thereof.

### Claim 7

A stable hybridoma that produces an antibody, wherein said antibody preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 8

A purified T cell subpopulation, wherein said T cells are specifically bound by an antibody or a combination of antibodies, wherein said antibody or said antibody combination preferentially binds a CDR3-loop or an α-β junction of a TCR; or wherein said antibody preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 9

A method of generating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said method comprising:
(a) coupling a cyclic peptide to a carrier;
(b) immunizing a mammal with said coupled peptide; and
(c) isolating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 10

A method of generating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said method comprising:
(a) immunizing a CD1 or invariant T cell deficient mammal with invariant T cells; and
(b) isolating an antibody that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein said mammal is a CD1d knockout mouse, a mammal tolerized to NK T cells, a mammal tolerized to CD1d-reactive T cells, a mammal tolerized to JαQ+ T cell, a mammal tolerized to the invariant TCR, a mammal in which invariant T cells have been removed, a mammal lacking part of the a chain of said TCR a chain, or a mammal lacking part of the β chain of said TCR.

### Claim 12

A method of measuring the amount of NK TCRs or the amount of NK T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 13

A method of measuring the amount of CD1d-reactive TCRs or the amount of CD1d-reactive T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 14

A method of measuring the amount of JαQ+ TCRs or the amount of JαQ+ T cells in a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 15

A method of visualizing the NK TCRs or the NK T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 16

A method of visualizing the CD1d-reactive TCRs or the CD1d-reactive T cells in a sample, said method comprising contacting said sample with an antibody that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 17

A method of visualizing the JαQ+ TCRs or the JαQ+ T cells in a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs.

### Claim 18

A method of diagnosing a subject with a condition or an increased risk for a condition selected from the group consisting of autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer; said method comprising the following:
(a) contacting a sample from said subject with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells;
(b) quantitating the amount of said antibody or said antibody combination bound to said TCR or said T cells; thereby determining the amount of T cells of interest in said sample; and
(c) comparing the amount of said T cells of interest in said sample to the amount of said T cells of interest found in subjects diagnosed with said condition or subjects not diagnosed with said condition.

### Claim 19 (depends on 18)

The method of claim 18, further comprising comparing the amount of another T cell type in said sample with the amount of said another T cell type found in subjects diagnosed with said condition or subjects not diagnosed with said condition.

### Claim 20

A method of treating or preventing an autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, or cancer in a mammal, said method comprising administering to said mammal an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 21

A method of inhibiting T cell pathogenesis in a mammal, said method comprising administering to said mammal an antibody or a combination of antibodies that preferentially binds a CDR3-loop, an antigen binding site, or an α-β junction of said TCRs; or inhibits the expansion of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said administering sufficient to inhibit a T cell expressing said TCR, a NIK T cell, a CD1d-reactive T cell, or a JαQ+ T cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein said antibody is covalently linked to a toxin or a radiolabel.

### Claim 23

A method of increasing the size of a subpopulation of T cells, said method comprising contacting a sample comprising said T cells with an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, JαQ+ T cells, and T cells expressing a CDR3-loop or an α-β junction of a TCR that is preferentially bound by said antibody, wherein said contacting occurs under conditions that result in an increase in the number of said T cells.

### Claim 24 (depends on 23)

The method of claim 23, further comprising contacting said sample with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is not α-galactosylceramide.

### Claim 25 (depends on 24)

The method of claim 24, wherein said antigen is a lipid or glycosyl-phosphatidylinositol antigen from an infectious pathogen, an antigen from a cancerous cell, or a self-lipid.

### Claim 26 (depends on 23)

The method of claim 23, further comprising contacting said sample with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is α-galactosylceramide.

### Claim 27

A method of increasing the size of a subpopulation of T cells, said method comprising:
(a) contacting a sample comprising said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
(b) isolating said complex; and
(c) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is not α-galactosylceramide.

### Claim 28 (depends on 27)

The method of claim 27, wherein said antigen is a lipid or glycosyl-phosphatidylinositol antigen from an infectious pathogen, an antigen from a cancerous cell, or a self-lipid.

### Claim 29

A method of increasing the size of a subpopulation of T cells, said method comprising:
(a) contacting a sample comprising said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
(b) isolating said complex; and
(c) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is wherein said antigen is α-galactosylceramide.

### Claim 30 (depends on 27, 29)

The method of claim 27 or 29, further comprising contacting said sample or said complex with one or more cytokines.

### Claim 31

A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
(a) obtaining a sample comprising said T cells from said mammal;
(b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, JαQ+ T cells, and T cells expressing a CDR3-loop or an α-β junction of a TCR that is preferentially bound by said antibody or said antibody combination; said contacting conducted under conditions that allow said contacting to increase the number of said T cells; and
(c) administering said contacted T cells to said mammal.

### Claim 32 (depends on 31)

The method of claim 31, further comprising purifying said T cells prior to said contacting step or after said contacting step.

### Claim 33

A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
(a) obtaining a sample comprising said T cells from said mammal;
(b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
(c) isolating said complex; and
(d) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is not α-galactosylceramide; and
(e) administering said contacted T cells to said mammal.

### Claim 34 (depends on 33)

The method of claim 33, wherein said antigen is a lipid or glycosyl-phosphatidylinositol antigen from an infectious pathogen, an antigen from a cancerous cell, or a self-lipid.

### Claim 35

A method of increasing the size of a subpopulation of T cells in a mammal, said method comprising:
(a) obtaining a sample comprising said T cells from said mammal;
(b) contacting said T cells with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells; said contacting conducted under conditions that allow complex formation between said T cells and said antibody or said combination of antibodies;
(c) isolating said complex; and
(d) contacting said T cells in said complex or recovered from said complex with an antigen and antigen presenting cells under conditions that allow said contacting to increase the number of said T cells; wherein said antigen is α-galactosylceramide; and
(e) administering said contacted T cells to said mammal.

### Claim 36 (depends on 33, 35)

The method of claim 33 or 35, further comprising administering one or more cytokines to said mammal.

### Claim 37 (depends on 33, 35)

The method of claim 33 or 35, further comprising contacting said sample or said T cells with one or more cytokines, wherein said contacting alters the ratio of Th1/Th2/immune deviation response by said contacted T cells

### Claim 38 (depends on 33, 35)

The method of claim 33 or 35, wherein said method is used in the treatment or prevention of an autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, or cancer in said mammal.

### Claim 39

A method of purifying a subpopulation of T cells from a sample, said method comprising contacting said sample with an antibody or a combination of antibodies that preferentially binds a CDR3-loop or an α-β junction of a TCR; or an antibody that preferentially binds or modulates the expansion or activation of at least one T cell subpopulation selected from the group of NK T cells, CD1d-reactive T cells, and JαQ+ T cells.

### Claim 40 (depends on 39)

The method of claim 39, further comprising contacting said sample with an anti-Vα24, CD4, CD8, CD56, CD161, or Vβ11 antibody.

### Claim 41 (depends on 39)

The method of claim 39, wherein said antibody is covalently linked to a fluorescent label, wherein said complex is isolated based on the fluorescence signal of said complex.

### Claim 42 (depends on 39)

The method of claim 39, wherein said antibody is covalently linked to a magnetic label, wherein said complex is isolated based on the magnetism of said complex.
